NSE: AUROPHARMA · 9 November 2026
- Aurobindo Pharma Ltd shares advanced by 2.84% today, settling at ₹1,855.30 against its previous close of ₹1,804.00. The stock opened at ₹1,810.60 and moved within a day's range of ₹1,800.70 to ₹1,856.10, touching a new 52-week high during the trading session.
- Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, registering its highest ever quarterly revenue of ₹10,263 crore, up 23.9% year-on-year. Quarterly net profit stood at ₹1,124 crore, representing a 32.5% increase compared to the same period last year. The company also declared an interim dividend of ₹7.00 per equity share with a record date of November 11, 2026.
- Trading volume was 2.28 times the 20-day average daily volume.
Why is Aurobindo Pharma share price rising on 9 November 2026?
Aurobindo Pharma Ltd shares advanced by 2.84% today, settling at ₹1,855.30 against its previous close of ₹1,804.00. The stock opened at ₹1,810.60 and moved within a day's range of ₹1,800.70 to ₹1,856.10, touching a new 52-week high during the trading session.
The broader market and sector backdrop showed positive momentum, with the benchmark Nifty edging up by 0.06% while the Nifty Pharma sector index outperformed significantly, posting a gain of 3.42%. Aurobindo Pharma's upward price action matches this strong sectoral tailwind, building on its recent performance trajectory that includes a 5-day return of 10.19% and a 20-day return of 9.59%.
24.12 lakh shares traded by 9 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 10.59 lakh shares (2.28 times). The five-day average daily volume was 17.19 lakh shares. Separately, the NSE report for 9 November 2026 showed 13.82 lakh shares delivered, representing 57.31% of that day’s traded volume. The same report recorded 120,364 trades.
The stock's 2.84% gain and new 52-week high are supported by broad outperformance in the Nifty Pharma sector index, high trading volumes exceeding its 20-day average, and continuing positive sentiment from its strong Q2 FY27 earnings report announced earlier in the month.
Latest Company Developments
Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, registering its highest ever quarterly revenue of ₹10,263 crore, up 23.9% year-on-year. Quarterly net profit stood at ₹1,124 crore, representing a 32.5% increase compared to the same period last year. The company also declared an interim dividend of ₹7.00 per equity share with a record date of November 11, 2026.
Demonstrates sustained operational expansion across key global formulations and API segments, directly supporting baseline valuation metrics.
The board approved the transfer of ownership of Auro Pharma LLC in Russia from Auro Active Pharma Private Limited to Auropharm Overseas Limited for a cash consideration of approximately ₹29 crore. Additionally, the board approved a proposal to merge Auroactive Pharma Private Limited into Apitoria Pharma Private Limited to consolidate API operations.
Streamlines group corporate structure and optimizes capacity utilization across manufacturing subsidiaries.
The board of directors approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Non-executive and Independent Director for a second term of five years commencing April 1, 2027, subject to shareholder approval via postal ballot. Mr. Kumar previously served as the Chairman of LIC of India.
Secures continuity in governance and oversight from experienced leadership.
Corporate Actions This Week: HUL, Dabur, Balrampur Chini, Aurobindo Pharma, ONGC, Jyothy Labs, And Many More In Focus NDTV Profit
a press release dated November 04, 2026, titled "Press release on Q2 FY27 Financial Results.".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.
The filing reported 44 MF/UTI holders.
Research & Brokerage Views
Maintained a positive outlook citing strong strategic positioning and market share expansion across key regulated geographies.
What to Watch Next
- Execution of the upcoming interim dividend record date scheduled for November 11, 2026
- Progress on the NCLT merger application involving Auroactive Pharma and Apitoria Pharma
- Integration milestones regarding the Lannett acquisition and new US product launches
- Sustained delivery percentage trends above the 50% threshold in subsequent trading sessions
Other Dated Coverage
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 4.69% | 5 November 2026 — 5 November 2026
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 2.43% | 23 October 2026 — 23 October 2026
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 1.41% | 22 October 2026 — 22 October 2026
More Aurobindo Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Aurobindo Pharma company news?
Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, registering its highest ever quarterly revenue of ₹10,263 crore, up 23.9% year-on-year. Quarterly net profit stood at ₹1,124 crore, representing a 32.5% increase compared to the same period last year. The company also declared an interim dividend of ₹7.00 per equity share with a record date of November 11, 2026.
How strong was Aurobindo Pharma’s trading volume?
24.12 lakh shares traded, 2.28 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.